Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.45 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5222514 | 1.00 | CYP2D6 (0.55) | CYP2D6CYP1A2CYP3A4CYP2C19ENPP3 | |
| SCHEMBL2632637 | 1.00 | CYP2D6 (0.55) | CYP2D6CYP1A2CYP3A4CYP2C19ENPP3 | |
| SCHEMBL12810140 | 1.00 | CYP2D6 (0.55) | CYP2D6CYP1A2CYP3A4CYP2C19ENPP3 | |
| SCHEMBL5222520 | 1.00 | CYP2D6 (0.55) | CYP2D6CYP1A2CYP3A4CYP2C19ENPP3 | |
| SCHEMBL5224782 | 0.97 | CYP2D6 (0.55) | CYP2D6CYP1A2CYP3A4CYP2C19ENPP3 | |
| SCHEMBL5224778 | 0.97 | CYP2D6 (0.55) | CYP2D6CYP1A2CYP3A4CYP2C19ENPP3 | |
| SCHEMBL5224786 | 0.97 | CYP2D6 (0.55) | CYP2D6CYP1A2CYP3A4CYP2C19ENPP3 | |
| SCHEMBL8744470 | 0.93 | CYP2D6 (0.60) | CYP2D6CYP1A2CYP3A4CYP2C19ENPP3 | |
| SCHEMBL8744474 | 0.93 | CYP2D6 (0.60) | CYP2D6CYP1A2CYP3A4CYP2C19ENPP3 | |
| SCHEMBL8744478 | 0.93 | CYP2D6 (0.60) | CYP2D6CYP1A2CYP3A4CYP2C19ENPP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070292875-A1 | Human RNase H1 oligonucleotide compositions thereof | ISIS PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070123702-A1 | Oligonucleotdies having A-DNA form and B-DNA form conformational geometry | MANOHARAN MUTHIAH | 2007-05-31 | — | — | US | disclosed |
| EP-1743901-A2 | Oligonucleotides having A-DNA or B-DNA form | ISIS PHARMACEUTICALS, INC. (US) | 2007-01-17 | — | — | EP | disclosed |
| US-7119184-B2 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | ISIS PHARMACEUTICALS, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1222309-B1 | HUMAN RNASE H AND OLIGONUCLEOTIDE COMPOSITIONS THEREOF | ISIS PHARMACEUTICALS INC (US) | 2005-12-07 | — | — | EP | disclosed |
| EP-1100809-B1 | RNA TARGETED 2'-MODIFIED OLIGONUCLEOTIDES THAT ARE CONFORMATIONALLY PREORGANIZED | ISIS PHARMACEUTICALS INC (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040102618-A1 | Human RNase H1 and oligonucleotide compositions thereof | ISIS PHARMACEUTICALS, INC. | 2004-05-27 | — | — | US | disclosed |
| US-6737520-B2 | FOR USE AS SUBSTRATE FOR RIBONUCLEASE AND CONTROLLING BINDING AFFINITY/NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS, INC. | 2004-05-18 | — | — | US | disclosed |
| US-6617442-B1 | Divided into two portions, one of which supports cleavage of target RNA; use in enhancing antisense therapies | ISIS PHARMACEUTICALS, INC. | 2003-09-09 | — | — | US | disclosed |
| US-20030105311-A1 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | ISIS PHARMACEUTICALS, INC. | 2003-06-05 | — | — | US | disclosed |
| EP-1180113-A4 | OLIGONUCLEOTIDES HAVING A-DNA FORM AND B-DNA FORM CONFORMATIONAL GEOMETRY | ISIS PHARMACEUTICALS INC (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1222309-A1 | HUMAN RNASE H AND OLIGONUCLEOTIDE COMPOSITIONS THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 2002-07-17 | — | — | EP | disclosed |
| US-6369209-B1 | AFFINITY AND NUCLEASE RESISTANCE WHILE CONCURRENTLY SERVING AS SUBSTRATES FOR RNASE H WHEN BOUND TO A TARGET RNA STRAND | ISIS PHARMACEUTICALS, INC. | 2002-04-09 | — | — | US | disclosed |
| EP-1100809-A4 | RNA TARGETED 2'-MODIFIED OLIGONUCLEOTIDES THAT ARE CONFORMATIONALLY PREORGANIZED | ISIS PHARMACEUTICALS INC (US) | 2002-02-27 | — | — | EP | disclosed |
| EP-1180113-A1 | OLIGONUCLEOTIDES HAVING A-DNA FORM AND B-DNA FORM CONFORMATIONAL GEOMETRY | ISIS PHARMACEUTICALS, INC. (US) | 2002-02-20 | — | — | EP | disclosed |
| US-6271358-B1 | FOR INHIBITING SPECIFIC GENE EXPRESSION; HAVING ENHANCED HYBRID BINDING AFFINITY AND/OR INCREASED NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS, INC. | 2001-08-07 | — | — | US | disclosed |
| EP-1100809-A1 | RNA TARGETED 2'-MODIFIED OLIGONUCLEOTIDES THAT ARE CONFORMATIONALLY PREORGANIZED | ISIS PHARMACEUTICALS, INC. (US) | 2001-05-23 | — | — | EP | disclosed |
| WO-2001023613-A1 | HUMAN RNASE H AND OLIGONUCLEOTIDE COMPOSITIONS THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 2001-04-05 | — | — | WO | disclosed |
| WO-2000066609-A1 | OLIGONUCLEOTIDES HAVING A-DNA FORM AND B-DNA FORM CONFORMATIONAL GEOMETRY | ISIS PHARMACEUTICALS, INC. (US) | 2000-11-09 | — | — | WO | disclosed |
| WO-2000006590-A1 | RNA TARGETED 2'-MODIFIED OLIGONUCLEOTIDES THAT ARE CONFORMATIONALLY PREORGANIZED | ISIS PHARMACEUTICALS, INC. (US) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105311-A1 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | RNGTT, RNASEH1, ADAR | CYP2D6 2259/4885CYP1A2 4324/4885CYP3A4 2794/4885 |
| US-20070292875-A1 | Human RNase H1 oligonucleotide compositions thereof | RNASEH1, RNASE1, RNASEL | CYP2D6 3440/4885CYP1A2 3652/4885CYP3A4 4236/4885 |
| US-20040102618-A1 | Human RNase H1 and oligonucleotide compositions thereof | RNASEH1, RNASE1, RNASEL | CYP2D6 3381/4885CYP1A2 3541/4885CYP3A4 4287/4885 |
| US-20070123702-A1 | Oligonucleotdies having A-DNA form and B-DNA form conformational geometry | RNASEH1, RNGTT, ADAR | CYP2D6 2277/4885CYP1A2 4597/4885CYP3A4 3270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.